v3.10.0.1
Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment - AstraZeneca (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 22, 2016
Jan. 31, 2019
Apr. 01, 2018
Jul. 02, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Business Acquisition [Line Items]              
Goodwill         $ 53,411,000,000 [1] $ 55,952,000,000 [1] $ 54,449,000,000
AstraZeneca [Member]              
Business Acquisition [Line Items]              
Payments to acquire businesses, cash portion $ 555,000,000         $ 605,000,000  
Milestone payment     $ 125,000,000 $ 50,000,000      
Potential milestone payments         75,000,000    
Maximum amount of sales-related payments         600,000,000    
Consideration transferred 1,040,000,000            
Fair value of contingent consideration 485,000,000            
Intangible assets 894,000,000            
Other current assets 92,000,000            
Goodwill 73,000,000            
Net deferred tax liabilities 19,000,000            
Minimum [Member] | AstraZeneca [Member]              
Business Acquisition [Line Items]              
Royalty payments         327,000,000    
Maximum [Member] | AstraZeneca [Member]              
Business Acquisition [Line Items]              
Royalty payments         $ 553,000,000    
Developed Technology Rights [Member] | AstraZeneca [Member]              
Business Acquisition [Line Items]              
Intangible assets 728,000,000            
In Process Research and Development [Member] | AstraZeneca [Member]              
Business Acquisition [Line Items]              
Intangible assets $ 166,000,000            
Subsequent Event [Member] | AstraZeneca [Member]              
Business Acquisition [Line Items]              
Deferred payment   $ 175,000,000          
[1] Amounts may not add due to rounding.